Using Modern Imaging Technology

Learn More

With new, proprietary drug formulations

Learn More

To precisely treat late stage and metastatic cancer

Learn More

and to stimulate a natural, adaptive immune response.

Learn More

Intensity Therapeutics is creating a new, highly effective cancer treatment - in situ vaccination.

Learn More

About Intensity Therapeutics

The Management

 

Founder and CEO

Lewis H. Bender

 

 

Prior to founding Intensity Therapeutics, from January 2008 until 2012 Mr. Bender was the CEO of Interleukin Genetics, a personalized medicine company.  At Interleukin Mr. Bender successfully restructured the Company, increased sales eight fold, developed a new genetic-based testing platform and partnered with a large insurance provider to initiate studies leading to reimbursement of the Company’s lead product.  Prior to joining Interleukin Genetics, Mr. Bender held numerous positions at Emisphere Technologies, Inc., a drug delivery company specializing in the oral delivery of poorly absorbed molecules. While at Emisphere from 1993 to December of 2007 Mr. Bender held positions as; Interim President & CEO, Chief Technology Officer, Senior Vice President of Business Development, and Vice President of Manufacturing and Process Development. During his career Mr. Bender has partnered with several major pharmaceutical and biotech companies using structures such as joint ventures, licensing and research collaboration agreements.  Mr. Bender has over 22 years of biotech and pharmaceutical experience having led teams taking products from discovery to Phase III for compounds using novel drug delivery techniques.  In addition, Mr. Bender has been successful in raising (or helping to raise) capital with institutional investors using several vehicles such as registered direct placements, PIPES, S-3 & S-1 filings, and convertible debt.  Most recently for Intensity Therapeutics he has raised approximately $2,200,000 in capital with investors.

Mr. Bender has both a S.B. and S.M. in Chemical Engineering from MIT, an MBA from UPENN’s Wharton School, and an MA in International studies also from UPENN. He spent several years living in Switzerland and speaks French, German and Swiss-German dialect.

 

Vice President and Chief Medical Officer
Ian B. Walters, MD

 


Dr. Walters has over 15 years of oncology/immunology drug development experience. Prior to joining Intensity Therapeutics Dr. Walters spent seven years at Bristol-Myers Squibb (BMS), where he led clinical research and matrix development teams. During his tenure there he contributed to the development of multiple immuno-oncology products (Yervoy® and Nivolimumab (anti-PD-1)), as well as the licensing and partnering strategy for other immuno-oncologic agents. Dr. Walters has worked in multiple biotech companies on corporate development, translational medicine, clinical development and medical affairs including Millennium Pharmaceuticals. Dr. Walters also has been a consultant to biotech, pharma and investment companies specializing in the evaluation, prioritization, and development of innovative technologies in the treatment of severe diseases. Before entering the private sector, Dr. Walters was a lead investigator at the Rockefeller University and initiated cutting edge immunology research to understand the mechanism of action of several compounds. Dr. Walters received his MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of The University of Pennsylvania.

 

Senior Vice President

Robert Cooke

 

 

Robert Cooke is currently Senior Vice President.  Mr. Cooke has nearly 20 years of medical imaging and industry experience. 
Mr. Cooke has served as Senior Vice President of Fujifilm Medical Systems USA, Inc.  responsible for all business functions of Fujifilm’s advanced imaging Modality Solutions and Medical Informatics Divisions.  Specific product areas included Fujifilm’s entire line of integrated information systems (in radiology), as well as breast imaging modalities and digital x-ray and ultrasound systems for both hospital and private practice facilities.


Most recently, Mr. Cooke founded, Imaging Elements the Radiology Meaningful Use solution and part time staff member for the Company.
Mr. Cooke received Bachelor of Science degrees in General Engineering and Computer Science from Trinity College in Hartford and has over 20 years of Medical Imaging and Healthcare Informatics industry experience.

Contact Us


Intensity Therapeutics, Inc.
8 Wright Street, Suite 107
Westport, CT 06880


Tel. (203) 682-2434
Fax (203) 664-1051


info@intensitytherapeutics.com

 

Click here for career inquiries

Who we are


Intensity Therapeutics is a clinical development stage company.  We are seeking partnerships/investors interested in advancing the company’s anti-cancer platform technology and lead product INT230-6.

 

Click here for inquiries

News